PAYS stock forecast, quote, news & analysis
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions... Show more
Paysign (PAYS) Stock Analysis: Pharma and Patient Affordability Expansion Drive a Rally Near 52-Week Highs
Key Takeaways
- Paysign shares are up roughly 7% over the trailing 30 days, holding near a 52-week high of $16.15 reached in mid-October 2026.
- The stock has delivered triple-digit year-to-date gains, supported by accelerating revenue growth across healthcare-related payment programs.
- Patient affordability and pharmaceutical copay assistance programs remain the fastest-growing segment, complementing the company's core plasma donor compensation business.
- Paysign beat second-quarter earnings estimates in early August 2026, extending a period of strong top-line momentum.
- Analyst coverage remains modest but constructive, with a consensus Buy rating and price targets near recent trading levels.
- The next confirmed earnings report is scheduled for November 9, 2026.
- For more detail on this ticker, explore Paysign's Price Targets, Earnings, and Forecast on dedicated pages.
- Investors can also explore Trending AI Robots for AI-driven trading strategies across the market.
Current Market Snapshot
Paysign, Inc. trades around $13.66, positioning the stock toward the upper end of its 52-week range of $3.08 to $16.15. The shares set a fresh 52-week high of $16.15 on October 20, 2026, before a modest pullback trimmed some of the gains. With a market capitalization of roughly $820 million, Paysign is a small-cap, growth-oriented fintech that has attracted investor attention through a multi-quarter expansion in its healthcare and pharmaceutical payment businesses.
The trailing 30-day move has been comparatively mild at around 7%, reflecting a period of consolidation after a stronger advance earlier in the year. Broader context helps frame the recent action: the stock has gained well over 100% year to date and more than 60% over the trailing three months, according to widely cited market data. Its five-year monthly beta of approximately 0.83 suggests the stock has been less volatile than the broader market despite its sizeable run. Valuation remains elevated relative to historical norms, with a trailing price-to-earnings ratio in the mid-50s, which keeps the focus firmly on continued execution and growth delivery.
Paysign (PAYS) Business Overview and Competitive Position
Founded in 2001 and headquartered in Henderson, Nevada, Paysign provides prepaid card programs, patient affordability offerings, digital banking services, and integrated payment processing for businesses, consumers, and government institutions. Its revenue streams include card program management fees, transaction and claim processing fees, interchange income, settlement income, and related service fees.
The company's two most important markets are plasma donor compensation and pharmaceutical patient affordability. In plasma, Paysign's Apheric platform facilitates reloadable debit card payments to donors, a market where the United States supplies a large share of global plasma and where the company has built meaningful share. In patient affordability, Paysign administers copay assistance programs for pharmaceutical manufacturers, using dynamic business rules to help reduce fund leakage and improve program efficiency. This segment has grown rapidly, supported by a steady flow of new program wins. The company's niche specialization, regulatory compliance infrastructure, bilingual 24/7 customer service, and proprietary program-management technology represent key competitive strengths.
Recent Developments Driving PAYS
Several verified developments have shaped investor sentiment over the past month. Paysign reported second-quarter results in early August 2026 that beat consensus earnings estimates, reinforcing confidence in its growth trajectory. The company's patient affordability business continues to expand its program count, and management has indicated an expectation of adding roughly 60 programs during the year, building on a base of roughly 140 active programs. First-quarter revenue of approximately $15.7 million compared with about $8.6 million in the prior-year period, illustrating the pace of expansion.
The company has also advanced its Apheric platform following its earlier acquisition of the Gamma donor-management technology, with the related donor-management system of record pending regulatory review. Analyst sentiment has turned more constructive during the year, with published price targets rising as revenue and margin assumptions improved. These factors, combined with broader investor interest in fintech and healthcare-payments themes, have supported the stock's elevated trading range even as day-to-day price action remains choppy.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a platform that offers hundreds of automated strategies trading thousands of tickers. Rather than listing every available bot, the section surfaces only the top-performing and most relevant strategies, helping users quickly identify tools that have demonstrated meaningful results. The bots vary widely in approach, holding timeframe, and performance metrics, ranging from short-term swing strategies to longer-horizon models. Because each bot operates with distinct rules and risk profiles, the page serves as a starting point for traders seeking to evaluate automated, data-driven approaches to the market. Visitors interested in exploring AI-powered trading signals can review the featured Trending AI Robots to assess which strategies may align with their objectives.
2026 Outlook and What Investors Should Watch
Looking ahead, several factors will likely influence Paysign's direction. The company's third-quarter earnings report, scheduled for November 9, 2026, will be a central event, with investors focused on revenue growth, program additions, and any update to full-year guidance. The pace of new pharmaceutical program signings and the trajectory of the patient affordability segment remain key growth indicators, while the plasma business continues to provide a stable, recurring foundation.
Regulatory developments represent a watch item, including the status of the company's donor-management system pending review. Seasonality is also relevant, as patient affordability activity is historically stronger in the first half of the year when insurance out-of-pocket maximums reset. Finally, given a premium valuation, execution against growth expectations and any shifts in analyst estimates or institutional positioning will be closely monitored. As with any high-growth, higher-multiple stock, investors should weigh upside potential against the inherent volatility and valuation risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PAYS in -30.97% downward trend, falling for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PAYS declined for three days, in 221 of 263 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PAYS as a result. In 64 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for PAYS turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 32 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
PAYS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for PAYS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAYS advanced for three days, in 251 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PAYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 202 of 245 cases where PAYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PAYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.933) is normal, around the industry mean (16.360). P/E Ratio (48.904) is within average values for comparable stocks, (53.310). Projected Growth (PEG Ratio) (1.840) is also within normal values, averaging (3.696). Dividend Yield (0.000) settles around the average of (0.434) among similar stocks. P/S Ratio (7.310) is also within normal values, averaging (104.492).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of payment solutions
Industry ComputerCommunications